DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Kizhakeyil A., Zaini NBM., Poh ZS., Wong BHS., Loh X., Ng AS., Low ZS., Prasannan P., Gong C., Tan MGK., Nagarajan C., Huang D., Lu PW., Lim JQ., Barrans S., Ong CK., Lim ST., Chng WJ., Follows G., Hodson DJ., Du MQ., Goh YT., Tan SH., Grigoropoulos NF., Verma NK.

DOI

10.1186/s12943-021-01437-0

Type

Journal article

Journal

Molecular Cancer

Publisher

Springer Science and Business Media LLC

Publication Date

12/2021

Volume

20

Permalink Original publication